For additional information on these trials, please contact Dr. Kelly Hume or Dr. Cheryl Balkman of the Cornell University Hospital for Animals Oncology Service at 607-253-3060.
More Clinical Trials
For more clinical trials opportunities, visit the Veterinary Medicine Clinical Trials website,
or contact the Clinical Research Coordinator at:
Kelly R. Hume
College of Veterinary Medicine
C3501C CPC, Box 31
Ithaca, NY 14853
P (607) 253-3516
F (607) 253-3055
Clinical Trials for Dr. Kelly Hume
TRIALS FOR CATS
Study title: DNA damage response mechanisms and chemosensitivity of feline injection site sarcomas
- Inclusion criteria: Cats suspected of having injection site sarcoma based on location and cytological evaluation (tumors may be primary, recurrent, or metastatic).
- Purpose: Determine whether alterations in DNA damage response mechanisms impact whether or not a given tumor is susceptible to chemotherapy. This study involves collection of tumor biopsies and in vitro laboratory analysis of those biopsies.
- Benefit: Study pays for pre-anesthetic bloodwork, three-view thoracic radiographs, biopsy procedure and associated anesthesia and histopathology charges.
Study title: Individualized dosing of carboplatin in cats with injection site sarcomas
- Inclusion criteria: Cats with histological confirmation of tumor type and a measurable primary tumor or metastatic lesion.
- Purpose: Determine the response rate and toxicity of carboplatin treatment (dosage based on GFR) in cats with injection site sarcomas. It is hypothesized that individualized dosing of carboplatin based on kidney function will be effective and well tolerated.
- Benefit: Study pays for cost of GFR, two carboplatin treatments, and CBC monitoring after treatment.
TRIALS FOR DOGS
Study title: A pilot study to determine if Palladia™induces hypothyroidism in dogs.
- Inclusion criteria: Dogs that are going to receive Palladia™ as part of their anti-cancer treatment.
- Exclusion criteria: Dogs that have thyroid carcinoma, dogs that have received neck irradiation, dogs that have life-threatening systemic illness, and/or dogs that are not expected to survive longer than 3 months.
- Purpose: To determine whether Palladia™ induces hypothyroidism in dogs and to assess the mechanism of this phenomenon.
- Benefit: Study pays for a 3 month supply of Palladia™ and for tests associated with monitoring thyroid gland function.
- Second Trial Site: Summit Veterinary Referral Center in Tacoma, WA.